Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $114.01M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 1.24M
Average 0.66M
UPB Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Upstream Bio, Inc.NASDAQ: UPB
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization turns negative
Q1 FY2026 depreciation & amortization was -$705K, compared with $43K a year earlier. Trailing-twelve-month depreciation & amortization was $2.39M.
Context
- Depreciation & amortization amounted to 46.0% of revenue in FY2025, up 42.3 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near -$705K or moves back toward the trailing-twelve-month quarterly average of $598.25K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- (1.31M) USD
- Year-over-year change
- -1576.4%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.31M) | -1576.4% |
| FY2024 | 2024-12-31 | 89K | +48.3% |
| FY2023 | 2023-12-31 | 60K | +757.1% |
| FY2022 | 2022-12-31 | 7K | — |
Depreciation & Amortization vs competitors
How UPB compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1910.9% is the highest of 9, against a peer median of -50.6%.
- Depreciation & amortization amounts to 72.0% of revenue for UPB, versus a peer median of 7.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $22.34M USD | -50.0% | -1.7% | 3.7% | |
| LTM Mar 2026 | $9.99M USD | -2.7% | +10.7% | 15.1% | |
| LTM Mar 2026 | $8.15M USD | -5.8% | -4.3% | 11.4% | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $2.39M USD | +1910.9% | — | 72.0% |
| LTM Jun 2026 | $2.21M USD | -55.0% | -4.9% | 21.4% | |
| LTM Mar 2026 | $1.05M USD | -922.8% | — | — | |
| LTM Sep 2026 | €483K EUR | +19.4% | +39.9% | — | |
| LTM Sep 2026 | $282K USD | -51.1% | +2.5% | — | |
| LTM Mar 2026 | $102K USD | -2140.0% | -43.3% | 0.0% | |
| LTM Sep 2026 | $0 USD | — | +72.0% | 0.0% | |
| Peer median (excluding UPB) | — | -50.6% | +0.4% | 7.5% | |
Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (23.87M) | (20.54M) | (62.81M) | (143.44M) |
| Depreciation & Amortization | 7K | 60K | 89K | (1.31M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.28M | 3.43M | 6M | 10.33M |
| Change in Working Capital | 3.41M | (4.31M) | 1.87M | 589K |
| Accounts Receivables | (412K) | 314K | (515K) | (55K) |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 462K | 1.28M | 2.02M | (1.28M) |
| Other Working Capital | 3.36M | (5.9M) | 371K | 1.93M |
| Other Non-Cash Items | 149K | (16.57M) | (4.33M) | 561K |
| Operating Cash Flow | (19.02M) | (37.93M) | (59.17M) | (133.28M) |
| Capital Expenditures | (82K) | (144K) | (511K) | (165K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (128.99M) | (290.61M) | (385.88M) |
| Sales of Investments | 0 | 46.29M | 231.64M | 292.56M |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (82K) | (82.84M) | (59.49M) | (93.48M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 9.96M | 129.55M | 272.72M | 2.44M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | (37K) | 118K | (3.74M) | 0 |
| Financing Cash Flow | 9.96M | 129.55M | 418.91M | 2.44M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | (9.14M) | 8.78M | 300.25M | (224.31M) |
| Free Cash Flow | (19.1M) | (38.07M) | (59.68M) | (133.28M) |
Upstream Bio, Inc.
NASDAQ:UPB
Intrinsic Alpha fair value
Locked
Current Price
$2.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.